skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
PEP-3-KLH Conjugate Vaccine (Code C74070)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: PEP-3-KLH Conjugate Vaccine

Definition: A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).

Display Name: PEP-3-KLH Conjugate Vaccine

Label: PEP-3-KLH Conjugate Vaccine

NCI Thesaurus Code: C74070 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1541477  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
PEP-3-KLH Conjugate Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 391254
PDQ Open Trial Search ID 391254 (check for NCI PDQ open clinical trial info)
UMLS CUI C1541477

Other Properties:
     Name Value (qualifiers indented underneath)
code C74070
Contributing_Source CTRP
Legacy_Concept_Name PEP-3-KLH_Conjugate_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom